Traws Pharma (TRAW) announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, ...
Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 ...
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback